Levosimendan In Ambulatory Heart Failure Patients
NCT04705337 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2025-05-09
Summary
The objective of the study is to determine the efficacy of repeated infusions of levosimendan in the group of outpatients with advanced systolic heart failure (HF).
Conditions
- Heart Failure New York Heart Association Class III
- Heart Failure New York Heart Association Class IV
- Heart Failure, Systolic
- Heart Failure With Reduced Ejection Fraction
Interventions
- DRUG
-
Levosimendan
administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
- OTHER
-
Placebo
administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Sponsors & Collaborators
-
Medical Research Agency, Poland
collaborator OTHER_GOV -
University of Opole
collaborator OTHER -
Medical University of Lodz
collaborator OTHER -
Poznan University of Medical Sciences
collaborator OTHER -
Nicolaus Copernicus University
collaborator OTHER -
National Institute of Cardiology, Warsaw, Poland
collaborator OTHER -
Azienda Ospedaliera dei Colli
collaborator OTHER -
John Paul II Hospital, Krakow
collaborator OTHER -
Medical University of Bialystok
lead OTHER
Principal Investigators
-
Agnieszka Tycińska, Prof. MD · Medical University of Bialystok
-
Marek Gierlotka, Prof. MD · University of Opole
-
Jarosław Kasprzak, Prof. MD · Medical University of Łódź
-
Jacek Kubica, Prof. MD · Nicolaus Copernicus University in Toruń
-
Grzegorz Grześk, Prof. MD · Nicolaus Copernicus University in Toruń
-
Jadwiga Nessler, Prof. MD · John Paul II Hospital, Krakow
-
Janina Stępińska, Prof. MD · Cardinal Stefan Wyszyński Institute of Cardiology
-
Ewa Straburzyńska-Migaj, Prof. MD · Poznan University of Medical Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-15
- Primary Completion
- 2024-02-29
- Completion
- 2024-08-15
Countries
- Poland
Study Locations
More Related Trials
-
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
NCT03437226 ·Status: UNKNOWN ·Phase: PHASE3
-
Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure
NCT00988806 ·Status: UNKNOWN ·Phase: PHASE4
-
Levosimendan in Acute Decompensated Heart Failure
NCT07262723 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
NCT02973620 ·Status: NO_LONGER_AVAILABLE
-
Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
NCT04917497 ·Status: COMPLETED
-
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
NCT00219388 ·Status: COMPLETED ·Phase: PHASE4
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
NCT01188369 ·Status: TERMINATED ·Phase: PHASE4
-
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
NCT05953831 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children
NCT01301313 ·Status: TERMINATED ·Phase: PHASE2
-
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
NCT04397302 ·Status: COMPLETED
-
Levosimendan Versus Dobutamine for Renal Function in Heart Failure
NCT02133105 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure
NCT01065194 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT05139615 ·Status: TERMINATED ·Phase: PHASE2
-
Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
NCT01221116 ·Status: TERMINATED ·Phase: NA
-
Early Management Strategies of Acute Heart Failure for Patients With NSTEMI
NCT03189901 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacokinetic Modelling of Levosimendan in Adults
NCT06993584 ·Status: NOT_YET_RECRUITING
-
A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure
NCT01120210 ·Status: COMPLETED ·Phase: PHASE2
-
European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure
NCT00696631 ·Status: TERMINATED ·Phase: PHASE3
-
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
NCT00505791 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction
NCT05508035 ·Status: RECRUITING ·Phase: PHASE3
-
Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery
NCT01595737 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969 ·Status: COMPLETED ·Phase: PHASE2
-
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure
NCT07218627 ·Status: RECRUITING ·Phase: PHASE1